November 3, 2025 — Leads & Copy — Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will participate in three upcoming investor conferences: the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025, in Boston; the UBS Global Healthcare Conference 2025 on November 12, 2025, in Palm Beach, FL; and the 2025 Jefferies London Healthcare Conference on November 19, 2025, in London.
Live webcasts and recordings will be available on Olema’s investor relations website, as permitted.
Olema Oncology is focused on targeted therapies for breast cancer and beyond. Its lead product candidate, palazestrant (OP-1250), is in two Phase 3 clinical trials, and OP-3136, a KAT6 inhibitor, is in a Phase 1 clinical study. The company is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
Courtney O’Konek, Vice President, Corporate Communications, media@olema.com
Source: Olema Pharmaceuticals, Inc.
Source: Olema Pharmaceuticals, Inc.
